Business Bites: Biomet's knee growth still slowing; Exact gets reimbursement boost
This article was originally published in Clinica
Executive Summary
Biomet saw sales increase 6% year-on-year during its first quarter, with its hip and knee franchises both growing 4%. But although this might appear a decent performance on the surface, it may disappoint observers who had hoped to see a turnaround in the stagnant large joint reconstructive market. Expectations were raised in Q3, when Biomet’s knee implant sales increased 8% (or 9% at constant currency rates), but then scotched in Q4 when growth in the division fell to 5%. The latest results won’t do much to encourage other players that the sector is back on the up.